# SENTARA HEALTH PLANS

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

**Directions**: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

**Drug Requested: Auvelity™** (dextromethorphan HBr and bupropion HCl ER tablets 45 mg/105 mg)

**MEMBER & PRESCRIBER INFORMATION:** Authorization may be delayed if incomplete.

**Member Name:** _____

**Member Sentara #:** _____ **Date of Birth:** _____

**Prescriber Name:** _____

**Prescriber Signature:** _____ **Date:** _____

**Office Contact Name:** _____

**Phone Number:** _____ **Fax Number:** _____

**NPI #:** _____

**DRUG INFORMATION:** Authorization may be delayed if incomplete.

**Drug Name/Form/Strength:** _____

**Dosing Schedule**: _____ **Length of Therapy**: _____

**Diagnosis:** _____ **ICD Code, if applicable:** _____

**Weight (if applicable):** _____ **Date weight obtained:** _____

**Recommended Dosage:** One tablet twice a day separated by at least 8 hours.

**CLINICAL CRITERIA:** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ❑ Member is 18 years of age or older
- ❑ Member has a diagnosis of major depressive disorder (MDD)
- ❑ Member must **NOT** have hypersensitivity to bupropion, dextromethorphan, or any component of the requested medication
- ❑ Provider attests that member has been screened for personal or family history of bipolar disorder, mania, and hypomania
- ❑ Provider attests that member is **NOT** undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs

**(Continued on next page)**

- ❑ Member will **NOT** take a monoamine oxidase inhibitor (MAOI) within 14 days of Auvelity™
- ❑ Member does **NOT** have any of the following:
  - A seizure disorder
  - A diagnosis of bulimia or anorexia nervosa
  - A diagnosis of severe hepatic or severe renal impairment
- ❑ Member has had at least a 30-day trial and failure of a serotonin-norepinephrine reuptake inhibitor (SNRI) (e.g., venlafaxine, desvenlafaxine, duloxetine) **(verified by chart notes or pharmacy paid claims)**
- ❑ Member has had at least a 30-day trial and failure of a selective serotonin reuptake inhibitor (SSRI) (e.g., citalopram, sertraline, fluoxetine) **(verified by chart notes or pharmacy paid claims)**
- ❑ Member has had at least a 30-day trial and failure of one other antidepressant agent (e.g., bupropion, mirtazapine, TCA) **(verified by chart notes or pharmacy paid claims)**

| **Check each drug that has been tried. If not checked, authorization process will be delayed.** | | |
|---|---|---|
| ❑ bupropion | ❑ citalopram | ❑ desvenlafaxine |
| ❑ duloxetine | ❑ escitalopram | ❑ fluoxetine |
| ❑ mirtazapine | ❑ paroxetine | ❑ sertraline |
| ❑ venlafaxine ER | ❑ Other: _____ | |

***Not all drugs may be covered under every Plan***

***If a drug is non-formulary on a Plan, documentation of medical necessity will be required.***

****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

***Approved by Pharmacy and Therapeutics Committee**: ~~10/19/2017; 5/25/2023;~~ **9/26/2024**
**REVISED/UPDATED/REFORMATTED:** ~~12/27/2017; 1/11/2018; 5/3/2018; 9/26/2018; 9/6/2019; 10/11/2021; 5/11/2023; 6/15/2023; 10/26/2023;~~ **10/15/2024**